Fresh analysis indicates that people who come off popular weight-loss injections like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who halt traditional diet and exercise regimens.
Findings released in a major medical journal points out that while overweight individuals frequently drop a large proportion of their total mass while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Individuals using these medications must be aware of the risk of quick weight regain when the treatment concludes," warns researcher Dr. Susan Jebb.
This pace of regain suggests a return to original weight in about 18 months.
Analyzing Approaches
The study, which examined dozens of trials involving over 9,000 of patients, compared the effects of the injectable medications with older methods.
The team note that individuals who lose weight through lifestyle changes alone usually have a slower weight regain—around 100 grams monthly—post-intervention.
Understanding the Rapid Regain
Doctors propose the mechanism of the drugs explains the amplified regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone levels far above than normal might result in the body to generate a reduced amount of its own natural GLP-1, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication results in appetite is uncontrolled, making overeating much more probable."
A Chronic Condition?
Medical guidelines recommend the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.
Many experts say that, considering the significant potential of weight regain, the therapy is often ongoing.
This perspective is supported by drug manufacturers, who state that the findings "highlight the persistent nature of excess weight," comparing it to managing diseases like high blood pressure.
User Testimonies
Individuals who have discontinued the medication describe a powerful resurgence of cravings.
"It was like a trigger flipping and I was suddenly ravenous," said an individual.
This difficulty is exacerbated if users have not established lasting lifestyle or habit modifications during treatment.
Significant Adoption
Survey data suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand remaining high.
- Adoption is greater among females than men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Finally, researchers emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and long-term success likely depends on ongoing behavioural management.
